/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

J

Jonathan R. LaRochelle

Relay Therapeutics (United States)(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

86

Papers

1.8K

Citations

20

h-index

21

i10-index

Jonathan R. LaRochelle is an academic researcher from Relay Therapeutics (United States). The author has contributed to research in topics: PI3K/AKT/mTOR signaling in cancer & Lung Cancer Treatments and Mutations & Metabolism and Genetic Disorders. The author has an h-index of 20, co-authored 74 publications.

ORCID: 0000-0002-3301-7904

Research Topics

PI3K/AKT/mTOR signaling in cancer Lung Cancer Treatments and Mutations Metabolism and Genetic Disorders Advanced Breast Cancer Therapies Protein Tyrosine Phosphatases

Papers by this author

works

Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition

2018 · Nature Communications · 163 citations

https://doi.org/10.1038/s41467-018-06823-9

Jonathan R. LaRochelle Michelle Fodor Vidyasiri Vemulapalli Morvarid Mohseni

Table S2 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

2024 · 0 citations

https://doi.org/10.1158/2159-8290.25191456.v1

Andreas Varkaris Ermira Pazolli Hakan Günaydin Qi Wang

Figure S5 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

2024 · 0 citations

https://doi.org/10.1158/2159-8290.25191471.v1

Andreas Varkaris Ermira Pazolli Hakan Günaydin Qi Wang

Table S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

2024 · 0 citations

https://doi.org/10.1158/2159-8290.25191453.v1

Andreas Varkaris Ermira Pazolli Hakan Günaydin Qi Wang

Figure S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

2024 · 0 citations

https://doi.org/10.1158/2159-8290.25183952.v1

Andreas Varkaris Ermira Pazolli Hakan Günaydin Qi Wang

Figure S2 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

2024 · 0 citations

https://doi.org/10.1158/2159-8290.25183955

Andreas Varkaris Ermira Pazolli Hakan Günaydin Qi Wang

Research topics

topics

PI3K/AKT/mTOR signaling in cancer

Lung Cancer Treatments and Mutations

Metabolism and Genetic Disorders

Advanced Breast Cancer Therapies

Protein Tyrosine Phosphatases

Chat about Author

Papers

Chat

Click to start Chat